Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study

BACKGROUND: V591 (TMV-083) is a live recombinant measles vector-based vaccine candidate expressing a pre-fusion stabilized SARS-CoV-2 spike protein. METHODS: We performed a randomized, placebo-controlled Phase I trial with an unblinded dose escalation and a double-blind treatment phase at 2 sites in...

Descripción completa

Detalles Bibliográficos
Autores principales: Launay, Odile, Artaud, Cécile, Lachâtre, Marie, Ait-Ahmed, Mohand, Klein, Jelle, Luong Nguyen, Liem Binh, Durier, Christine, Jansen, Bastiaan, Tomberger, Yvonne, Jolly, Nathalie, Grossmann, Anna, Tabbal, Houda, Brunet, Jérémy, Gransagne, Marion, Choucha, Zaineb, Batalie, Damien, Delgado, Ana, Müllner, Matthias, Tschismarov, Roland, Berghmans, Pieter-Jan, Martin, Annette, Ramsauer, Katrin, Escriou, Nicolas, Gerke, Christiane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761070/
https://www.ncbi.nlm.nih.gov/pubmed/35045362
http://dx.doi.org/10.1016/j.ebiom.2021.103810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761070/
https://www.ncbi.nlm.nih.gov/pubmed/35045362
http://dx.doi.org/10.1016/j.ebiom.2021.103810

Ejemplares similares